<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466267</url>
  </required_header>
  <id_info>
    <org_study_id>anti-EGFR-antibody</org_study_id>
    <nct_id>NCT04466267</nct_id>
  </id_info>
  <brief_title>The Molecular Mechanism of RAS Wild-type mCRC Resistance to Anti-EGFR-antibody</brief_title>
  <official_title>The Molecular Mechanism of RAS Wild-type Metastatic Colorectal Cancer (mCRC) Resistance to Anti Epidermal Growth Factor Receptor (EGFR) Antibody</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Establishing the genetic map of primary and secondary resistance of Chinese wild RAS
      colorectal cancer received anti-EGFR treatment through tissues and peripheral blood NGS
      testing. Combination genetic data with clinical characteristics, prognosis and treatment data
      to explore the molecular mechanism of resistance of anti-EGFR-antibody.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cetuximab is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor
      receptor (EGFR) inhibitor. Many large clinical trials demonstrated that for RAS wild-type
      metastatic colorectal cancer (mCRC), especially left-sided RAS wild-type mCRC, cetuximab can
      prolong OS. But some of patients have primary resistance to cetuximab and for all patients
      received cetuximab will develop secondary resistance. Cell-free or circulating tumour DNA
      (ctDNA) including primary site and metastatic site genetic information, which can avoid tumor
      heterogeneity. The results of paired test detection of tissue and ctDNA showed there is 93%
      consistency in RAS testing. Therefore, dynamic monitoring ctDNA during anti-EGFR targeted
      treatment of RAS wild-type mCRC patients can implement prognosis of efficacy and response
      evaluation in real-time. Besides, it can monitor the variation features of resistance gene
      and find resistance gene in real-time. According the situation of gene change to find
      potential drug resistance mechanism and formulate individualization treatment plan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">July 4, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The molecular mechanism of patients primary or secondary resistance to cetuximab</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Dynamic monitoring ctDNA to identify potential molecular mechanism of RAS wild-type mCRC patients primary or secondary resistance to cetuximab</description>
  </primary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Colorectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissues and peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        RAS wild-type metastatic colorectal cancer patients treatment with FOLFOX/FORFIRI +
        cetuximab
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≥18 years, ≤75 years, all gender;

          2. Histologically proven metastatic adenocarcinoma of colorectal cancer, no previous
             history of cancer;

          3. The clinical data of patient is intact;

          4. The data of patients after surgery is intact, and the prognosis follow-up data of
             patient is available.

        Exclusion Criteria:

          1. Previous history of cancer；

          2. Intact clinical data or diagnosis results of histopathology is unavailable;

          3. Time of progression disease after treatment and follow-up data are unavailable;

          4. Patient received blood transfusion within 3 months;

          5. Other situation that researchers think it will impact the results of trails or violate
             ethics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Jin, MD.,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Oncology,Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.</citation>
    <PMID>28632865</PMID>
  </reference>
  <reference>
    <citation>Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 investigators. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016 Oct;17(10):1426-1434. doi: 10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420. Erratum in: Lancet Oncol. 2016 Nov;17 (11):e479.</citation>
    <PMID>27575024</PMID>
  </reference>
  <reference>
    <citation>Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017 Feb 1;3(2):194-201. doi: 10.1001/jamaoncol.2016.3797. Erratum in: JAMA Oncol. 2017 Dec 1;3(12):1742.</citation>
    <PMID>27722750</PMID>
  </reference>
  <reference>
    <citation>Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. 2017 Mar 1;28(3):468-477. doi: 10.1093/annonc/mdw619. Review. Erratum in: Ann Oncol. 2019 Nov 1;30(11):1845. Ann Oncol. 2019 Nov;30(11):1845.</citation>
    <PMID>27998963</PMID>
  </reference>
  <reference>
    <citation>Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E, Vidal Y, Candamio S, Vázquez F, Ruiz J, Guix M, Visa L, Sikri V, Albanell J, Bellosillo B, López R, Montagut C. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017 Jun 1;28(6):1325-1332. doi: 10.1093/annonc/mdx125.</citation>
    <PMID>28419195</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ruihua Xu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

